Pharma Companies Fined for Pay-For-Delay Agreements

The UK’s Competition and Markets Authority has imposed fines of £45 million on GlaxoSmithKline and suppliers of generic medicines for pay-for-delay agreements.

FacebookTwitterGoogle+XINGLinkedIn